#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The Mediterranean diet ( MD ) has been recognized as a model of healthy eating because of its contribution to a healthy lifestyle and a better quality of life .
3-1	17-20	The	abstract[3]	new[3]	appos	3-5[0_3]
3-2	21-34	Mediterranean	abstract[3]	new[3]	_	_
3-3	35-39	diet	abstract[3]	new[3]	_	_
3-4	40-41	(	_	_	_	_
3-5	42-44	MD	abstract	giv	coref	4-1[11_0]
3-6	45-46	)	_	_	_	_
3-7	47-50	has	_	_	_	_
3-8	51-55	been	_	_	_	_
3-9	56-66	recognized	_	_	_	_
3-10	67-69	as	_	_	_	_
3-11	70-71	a	_	_	_	_
3-12	72-77	model	_	_	_	_
3-13	78-80	of	_	_	_	_
3-14	81-88	healthy	abstract[5]	new[5]	ana	3-18[0_5]
3-15	89-95	eating	abstract[5]	new[5]	_	_
3-16	96-103	because	_	_	_	_
3-17	104-106	of	_	_	_	_
3-18	107-110	its	abstract|abstract[7]	giv|new[7]	_	_
3-19	111-123	contribution	abstract[7]	new[7]	_	_
3-20	124-126	to	abstract[7]	new[7]	_	_
3-21	127-128	a	abstract[7]|abstract[8]	new[7]|new[8]	coref	5-39[22_8]
3-22	129-136	healthy	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-23	137-146	lifestyle	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-24	147-150	and	abstract[7]	new[7]	_	_
3-25	151-152	a	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-26	153-159	better	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-27	160-167	quality	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-28	168-170	of	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-29	171-175	life	abstract[7]|abstract[9]|abstract	new[7]|new[9]|new	coref	5-14[18_0]
3-30	176-177	.	_	_	_	_

#Text=The MD is much more than a dietary pattern .
4-1	178-181	The	abstract[11]	giv[11]	coref	5-1[15_11]
4-2	182-184	MD	abstract[11]	giv[11]	_	_
4-3	185-187	is	_	_	_	_
4-4	188-192	much	_	_	_	_
4-5	193-197	more	_	_	_	_
4-6	198-202	than	_	_	_	_
4-7	203-204	a	abstract[13]	new[13]	_	_
4-8	205-212	dietary	event|abstract[13]	new|new[13]	coref	6-17
4-9	213-220	pattern	abstract[13]	new[13]	_	_
4-10	221-222	.	_	_	_	_

#Text=The word diet comes from the Greek diaita and means ‘ way of life ’ and the MD holds true to this meaning as MD covers not only what to eat but how to eat and live ( active lifestyle , prioritizing culinary activities , etc. ) .
5-1	223-226	The	abstract[15]	giv[15]	coref	5-17[19_15]
5-2	227-231	word	abstract|abstract[15]	new|giv[15]	_	_
5-3	232-236	diet	abstract[15]	giv[15]	_	_
5-4	237-242	comes	_	_	_	_
5-5	243-247	from	_	_	_	_
5-6	248-251	the	abstract[16]	new[16]	_	_
5-7	252-257	Greek	abstract[16]	new[16]	_	_
5-8	258-264	diaita	abstract[16]	new[16]	_	_
5-9	265-268	and	_	_	_	_
5-10	269-274	means	abstract	new	coref|none	5-22[20_0]|5-10[0_20]
5-11	275-276	‘	abstract[17]	new[17]	_	_
5-12	277-280	way	abstract[17]	new[17]	_	_
5-13	281-283	of	abstract[17]	new[17]	_	_
5-14	284-288	life	abstract[17]|abstract[18]	new[17]|giv[18]	_	_
5-15	289-290	’	abstract[17]|abstract[18]	new[17]|giv[18]	_	_
5-16	291-294	and	abstract[17]	new[17]	_	_
5-17	295-298	the	abstract[17]|abstract[19]	new[17]|giv[19]	coref	5-25[0_19]
5-18	299-301	MD	abstract[17]|abstract[19]	new[17]|giv[19]	_	_
5-19	302-307	holds	_	_	_	_
5-20	308-312	true	_	_	_	_
5-21	313-315	to	_	_	_	_
5-22	316-320	this	abstract[20]	new[20]	_	_
5-23	321-328	meaning	abstract[20]	new[20]	_	_
5-24	329-331	as	_	_	_	_
5-25	332-334	MD	abstract	giv	coref	7-4[32_0]
5-26	335-341	covers	_	_	_	_
5-27	342-345	not	_	_	_	_
5-28	346-350	only	_	_	_	_
5-29	351-355	what	_	_	_	_
5-30	356-358	to	_	_	_	_
5-31	359-362	eat	_	_	_	_
5-32	363-366	but	_	_	_	_
5-33	367-370	how	_	_	_	_
5-34	371-373	to	_	_	_	_
5-35	374-377	eat	_	_	_	_
5-36	378-381	and	_	_	_	_
5-37	382-386	live	_	_	_	_
5-38	387-388	(	_	_	_	_
5-39	389-395	active	abstract[22]	giv[22]	ana	6-2[0_22]
5-40	396-405	lifestyle	abstract[22]	giv[22]	_	_
5-41	406-407	,	_	_	_	_
5-42	408-420	prioritizing	_	_	_	_
5-43	421-429	culinary	abstract[23]	new[23]	_	_
5-44	430-440	activities	abstract[23]	new[23]	_	_
5-45	441-442	,	_	_	_	_
5-46	443-447	etc.	_	_	_	_
5-47	448-449	)	_	_	_	_
5-48	450-451	.	_	_	_	_

#Text=And it should be preserved in the Mediterranean basin where , in the past decades , dietary trends are departing from traditional dietary patterns .
6-1	452-455	And	_	_	_	_
6-2	456-458	it	abstract	giv	_	_
6-3	459-465	should	_	_	_	_
6-4	466-468	be	_	_	_	_
6-5	469-478	preserved	_	_	_	_
6-6	479-481	in	_	_	_	_
6-7	482-485	the	place[25]	new[25]	_	_
6-8	486-499	Mediterranean	place[25]	new[25]	_	_
6-9	500-505	basin	place[25]	new[25]	_	_
6-10	506-511	where	_	_	_	_
6-11	512-513	,	_	_	_	_
6-12	514-516	in	_	_	_	_
6-13	517-520	the	time[26]	new[26]	_	_
6-14	521-525	past	time[26]	new[26]	_	_
6-15	526-533	decades	time[26]	new[26]	_	_
6-16	534-535	,	_	_	_	_
6-17	536-543	dietary	abstract|abstract[28]	giv|new[28]	coref|coref|coref|coref	6-23|9-14[82_28]|6-23|9-14[82_28]
6-18	544-550	trends	abstract[28]	new[28]	_	_
6-19	551-554	are	_	_	_	_
6-20	555-564	departing	_	_	_	_
6-21	565-569	from	_	_	_	_
6-22	570-581	traditional	abstract[30]	new[30]	_	_
6-23	582-589	dietary	abstract|abstract[30]	giv|new[30]	coref	9-14
6-24	590-598	patterns	abstract[30]	new[30]	_	_
6-25	599-600	.	_	_	_	_

#Text=The principles underlying the MD — widely documented elsewhere — can be summarized as follows :
7-1	601-604	The	abstract[31]	new[31]	_	_
7-2	605-615	principles	abstract[31]	new[31]	_	_
7-3	616-626	underlying	_	_	_	_
7-4	627-630	the	abstract[32]	giv[32]	coref	9-1[79_32]
7-5	631-633	MD	abstract[32]	giv[32]	_	_
7-6	634-635	—	_	_	_	_
7-7	636-642	widely	_	_	_	_
7-8	643-653	documented	_	_	_	_
7-9	654-663	elsewhere	_	_	_	_
7-10	664-665	—	_	_	_	_
7-11	666-669	can	_	_	_	_
7-12	670-672	be	_	_	_	_
7-13	673-683	summarized	_	_	_	_
7-14	684-686	as	_	_	_	_
7-15	687-694	follows	_	_	_	_
7-16	695-696	:	_	_	_	_

#Text=high consumption of fruits , vegetables , cereals ( especially whole seeds ) , legumes , and nuts ; relatively high fat consumption ( up to 40 % of total energy intake ) , mainly monounsaturated fatty acids ( MUFAs ) from extra-virgin olive oil , the main fat used for seasoning and cooking ; moderate to high consumption of fish ; moderate dairy product consumption , usually in the form of yogurt and cheese ; low red meat and meat product consumption ; moderate alcohol consumption , mainly in the form of red wine during meals ; low consumption of simple sugars ( pastries , soft drinks , etc. ) ; and high consumption of herbs and spices — an important source of micronutrients , including calcium ( Ca ) — used to flavor dishes .
8-1	697-701	high	abstract[33]	new[33]	coref	8-63[54_33]
8-2	702-713	consumption	abstract[33]	new[33]	_	_
8-3	714-716	of	abstract[33]	new[33]	_	_
8-4	717-723	fruits	abstract[33]|plant	new[33]|new	_	_
8-5	724-725	,	abstract[33]	new[33]	_	_
8-6	726-736	vegetables	abstract[33]|plant	new[33]|new	_	_
8-7	737-738	,	abstract[33]	new[33]	_	_
8-8	739-746	cereals	abstract[33]|plant	new[33]|new	_	_
8-9	747-748	(	abstract[33]	new[33]	_	_
8-10	749-759	especially	abstract[33]	new[33]	_	_
8-11	760-765	whole	abstract[33]	new[33]	_	_
8-12	766-771	seeds	abstract[33]	new[33]	_	_
8-13	772-773	)	abstract[33]	new[33]	_	_
8-14	774-775	,	abstract[33]	new[33]	_	_
8-15	776-783	legumes	abstract[33]|substance	new[33]|new	_	_
8-16	784-785	,	abstract[33]	new[33]	_	_
8-17	786-789	and	abstract[33]	new[33]	_	_
8-18	790-794	nuts	abstract[33]|plant[38]	new[33]|new[38]	_	_
8-19	795-796	;	abstract[33]|plant[38]	new[33]|new[38]	_	_
8-20	797-807	relatively	abstract[33]|plant[38]|abstract[40]	new[33]|new[38]|new[40]	coref	8-58[50_40]
8-21	808-812	high	abstract[33]|plant[38]|abstract[40]	new[33]|new[38]|new[40]	_	_
8-22	813-816	fat	abstract[33]|plant[38]|substance|abstract[40]	new[33]|new[38]|new|new[40]	coref	8-47[48_0]
8-23	817-828	consumption	abstract[33]|plant[38]|abstract[40]	new[33]|new[38]|new[40]	_	_
8-24	829-830	(	abstract[33]|plant[38]|abstract[40]	new[33]|new[38]|new[40]	_	_
8-25	831-833	up	abstract[33]|plant[38]|abstract[40]	new[33]|new[38]|new[40]	_	_
8-26	834-836	to	abstract[33]|plant[38]|abstract[40]	new[33]|new[38]|new[40]	_	_
8-27	837-839	40	abstract[33]|plant[38]|abstract[40]|quantity[41]	new[33]|new[38]|new[40]|new[41]	_	_
8-28	840-841	%	abstract[33]|plant[38]|abstract[40]|quantity[41]	new[33]|new[38]|new[40]|new[41]	_	_
8-29	842-844	of	abstract[33]|plant[38]|abstract[40]|quantity[41]	new[33]|new[38]|new[40]|new[41]	_	_
8-30	845-850	total	abstract[33]|plant[38]|abstract[40]|quantity[41]|abstract[43]	new[33]|new[38]|new[40]|new[41]|new[43]	_	_
8-31	851-857	energy	abstract[33]|plant[38]|abstract[40]|quantity[41]|substance|abstract[43]	new[33]|new[38]|new[40]|new[41]|new|new[43]	_	_
8-32	858-864	intake	abstract[33]|plant[38]|abstract[40]|quantity[41]|abstract[43]	new[33]|new[38]|new[40]|new[41]|new[43]	_	_
8-33	865-866	)	abstract[33]|plant[38]|abstract[40]	new[33]|new[38]|new[40]	_	_
8-34	867-868	,	abstract[33]	new[33]	_	_
8-35	869-875	mainly	abstract[33]|substance[44]	new[33]|new[44]	appos	8-40[0_44]
8-36	876-891	monounsaturated	abstract[33]|substance[44]	new[33]|new[44]	_	_
8-37	892-897	fatty	abstract[33]|substance[44]	new[33]|new[44]	_	_
8-38	898-903	acids	abstract[33]|substance[44]	new[33]|new[44]	_	_
8-39	904-905	(	_	_	_	_
8-40	906-911	MUFAs	substance	giv	_	_
8-41	912-913	)	_	_	_	_
8-42	914-918	from	_	_	_	_
8-43	919-931	extra-virgin	substance[47]	new[47]	_	_
8-44	932-937	olive	object|substance[47]	new|new[47]	_	_
8-45	938-941	oil	substance[47]	new[47]	_	_
8-46	942-943	,	_	_	_	_
8-47	944-947	the	substance[48]	giv[48]	_	_
8-48	948-952	main	substance[48]	giv[48]	_	_
8-49	953-956	fat	substance[48]	giv[48]	_	_
8-50	957-961	used	_	_	_	_
8-51	962-965	for	_	_	_	_
8-52	966-975	seasoning	substance	new	_	_
8-53	976-979	and	_	_	_	_
8-54	980-987	cooking	_	_	_	_
8-55	988-989	;	_	_	_	_
8-56	990-998	moderate	_	_	_	_
8-57	999-1001	to	_	_	_	_
8-58	1002-1006	high	abstract[50]	giv[50]	coref	8-81[61_50]
8-59	1007-1018	consumption	abstract[50]	giv[50]	_	_
8-60	1019-1021	of	abstract[50]	giv[50]	_	_
8-61	1022-1026	fish	abstract[50]|animal	giv[50]|new	_	_
8-62	1027-1028	;	_	_	_	_
8-63	1029-1037	moderate	abstract[54]	giv[54]	_	_
8-64	1038-1043	dairy	substance|abstract[54]	new|giv[54]	_	_
8-65	1044-1051	product	substance|abstract[54]	new|giv[54]	coref	8-82
8-66	1052-1063	consumption	abstract[54]	giv[54]	_	_
8-67	1064-1065	,	abstract[54]	giv[54]	_	_
8-68	1066-1073	usually	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-69	1074-1076	in	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-70	1077-1080	the	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-71	1081-1085	form	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-72	1086-1088	of	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-73	1089-1095	yogurt	abstract[54]|abstract[55]|substance	giv[54]|new[55]|new	_	_
8-74	1096-1099	and	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-75	1100-1106	cheese	abstract[54]|abstract[55]|substance	giv[54]|new[55]|new	_	_
8-76	1107-1108	;	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-77	1109-1112	low	abstract[54]|abstract[55]|substance[58]	giv[54]|new[55]|new[58]	coref	8-81[0_58]
8-78	1113-1116	red	abstract[54]|abstract[55]|substance[58]	giv[54]|new[55]|new[58]	_	_
8-79	1117-1121	meat	abstract[54]|abstract[55]|substance[58]	giv[54]|new[55]|new[58]	_	_
8-80	1122-1125	and	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-81	1126-1130	meat	abstract[54]|abstract[55]|substance|abstract[61]	giv[54]|new[55]|giv|giv[61]	coref|coref	8-85[63_61]|8-85[63_61]
8-82	1131-1138	product	abstract[54]|abstract[55]|abstract|abstract[61]	giv[54]|new[55]|giv|giv[61]	_	_
8-83	1139-1150	consumption	abstract[54]|abstract[55]|abstract[61]	giv[54]|new[55]|giv[61]	_	_
8-84	1151-1152	;	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
8-85	1153-1161	moderate	abstract[54]|abstract[55]|abstract[63]	giv[54]|new[55]|giv[63]	_	_
8-86	1162-1169	alcohol	abstract[54]|abstract[55]|substance|abstract[63]	giv[54]|new[55]|new|giv[63]	_	_
8-87	1170-1181	consumption	abstract[54]|abstract[55]|abstract[63]	giv[54]|new[55]|giv[63]	_	_
8-88	1182-1183	,	abstract[54]|abstract[55]|abstract[63]	giv[54]|new[55]|giv[63]	_	_
8-89	1184-1190	mainly	abstract[54]|abstract[55]|abstract[63]|abstract[64]	giv[54]|new[55]|giv[63]|new[64]	_	_
8-90	1191-1193	in	abstract[54]|abstract[55]|abstract[63]|abstract[64]	giv[54]|new[55]|giv[63]|new[64]	_	_
8-91	1194-1197	the	abstract[54]|abstract[55]|abstract[63]|abstract[64]	giv[54]|new[55]|giv[63]|new[64]	_	_
8-92	1198-1202	form	abstract[54]|abstract[55]|abstract[63]|abstract[64]	giv[54]|new[55]|giv[63]|new[64]	_	_
8-93	1203-1205	of	abstract[54]|abstract[55]|abstract[63]|abstract[64]	giv[54]|new[55]|giv[63]|new[64]	_	_
8-94	1206-1209	red	abstract[54]|abstract[55]|abstract[63]|abstract[64]|substance[65]	giv[54]|new[55]|giv[63]|new[64]|new[65]	_	_
8-95	1210-1214	wine	abstract[54]|abstract[55]|abstract[63]|abstract[64]|substance[65]	giv[54]|new[55]|giv[63]|new[64]|new[65]	_	_
8-96	1215-1221	during	abstract[54]|abstract[55]|abstract[63]|abstract[64]|substance[65]	giv[54]|new[55]|giv[63]|new[64]|new[65]	_	_
8-97	1222-1227	meals	abstract[54]|abstract[55]|abstract[63]|abstract[64]|substance[65]|event	giv[54]|new[55]|giv[63]|new[64]|new[65]|new	_	_
8-98	1228-1229	;	abstract[54]|abstract[55]|abstract[63]|abstract[64]	giv[54]|new[55]|giv[63]|new[64]	_	_
8-99	1230-1233	low	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-100	1234-1245	consumption	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-101	1246-1248	of	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-102	1249-1255	simple	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|substance[68]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[68]	_	_
8-103	1256-1262	sugars	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|substance[68]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[68]	_	_
8-104	1263-1264	(	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-105	1265-1273	pastries	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|substance	giv[54]|new[55]|giv[63]|new[64]|new[67]|new	_	_
8-106	1274-1275	,	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-107	1276-1280	soft	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|substance[70]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[70]	_	_
8-108	1281-1287	drinks	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|substance[70]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[70]	_	_
8-109	1288-1289	,	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-110	1290-1294	etc.	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-111	1295-1296	)	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-112	1297-1298	;	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-113	1299-1302	and	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]	giv[54]|new[55]|giv[63]|new[64]|new[67]	_	_
8-114	1303-1307	high	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]	_	_
8-115	1308-1319	consumption	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]	_	_
8-116	1320-1322	of	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]	_	_
8-117	1323-1328	herbs	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|plant	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new	_	_
8-118	1329-1332	and	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]	_	_
8-119	1333-1339	spices	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|plant	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new	_	_
8-120	1340-1341	—	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]	_	_
8-121	1342-1344	an	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]	_	_
8-122	1345-1354	important	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]	_	_
8-123	1355-1361	source	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]	_	_
8-124	1362-1364	of	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]	_	_
8-125	1365-1379	micronutrients	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]|substance[75]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]|new[75]	_	_
8-126	1380-1381	,	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]|substance[75]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]|new[75]	_	_
8-127	1382-1391	including	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]|substance[75]	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]|new[75]	_	_
8-128	1392-1399	calcium	abstract[54]|abstract[55]|abstract[63]|abstract[64]|abstract[67]|abstract[71]|abstract[74]|substance[75]|substance	giv[54]|new[55]|giv[63]|new[64]|new[67]|new[71]|new[74]|new[75]|new	_	_
8-129	1400-1401	(	_	_	_	_
8-130	1402-1404	Ca	person	new	_	_
8-131	1405-1406	)	_	_	_	_
8-132	1407-1408	—	_	_	_	_
8-133	1409-1413	used	_	_	_	_
8-134	1414-1416	to	_	_	_	_
8-135	1417-1423	flavor	_	_	_	_
8-136	1424-1430	dishes	object	new	_	_
8-137	1431-1432	.	_	_	_	_

#Text=This traditional diet , however , has been affected by the onslaught of dietary trends of recent decades .
9-1	1433-1437	This	abstract[79]	giv[79]	coref	19-1[177_79]
9-2	1438-1449	traditional	abstract[79]	giv[79]	_	_
9-3	1450-1454	diet	abstract[79]	giv[79]	_	_
9-4	1455-1456	,	_	_	_	_
9-5	1457-1464	however	_	_	_	_
9-6	1465-1466	,	_	_	_	_
9-7	1467-1470	has	_	_	_	_
9-8	1471-1475	been	_	_	_	_
9-9	1476-1484	affected	_	_	_	_
9-10	1485-1487	by	_	_	_	_
9-11	1488-1491	the	abstract[80]	new[80]	_	_
9-12	1492-1501	onslaught	abstract[80]	new[80]	_	_
9-13	1502-1504	of	abstract[80]	new[80]	_	_
9-14	1505-1512	dietary	abstract[80]|abstract|abstract[82]	new[80]|giv|giv[82]	coref|coref	26-6|26-6
9-15	1513-1519	trends	abstract[80]|abstract[82]	new[80]|giv[82]	_	_
9-16	1520-1522	of	abstract[80]|abstract[82]	new[80]|giv[82]	_	_
9-17	1523-1529	recent	abstract[80]|abstract[82]|time[83]	new[80]|giv[82]|new[83]	_	_
9-18	1530-1537	decades	abstract[80]|abstract[82]|time[83]	new[80]|giv[82]|new[83]	_	_
9-19	1538-1539	.	_	_	_	_

#Text=Osteoporosis ( OP ) is among the diseases with the highest incidence in advanced age , i. e. , coronary heart diseases , cancer , respiratory system diseases , depression , and neurodegenerative diseases such as Alzheimer ’s disease .
10-1	1540-1552	Osteoporosis	abstract	new	appos	10-3
10-2	1553-1554	(	_	_	_	_
10-3	1555-1557	OP	abstract	giv	coref	10-7[86_0]
10-4	1558-1559	)	_	_	_	_
10-5	1560-1562	is	_	_	_	_
10-6	1563-1568	among	_	_	_	_
10-7	1569-1572	the	abstract[86]	giv[86]	coref	11-3[0_86]
10-8	1573-1581	diseases	abstract[86]	giv[86]	_	_
10-9	1582-1586	with	abstract[86]	giv[86]	_	_
10-10	1587-1590	the	abstract[86]|abstract[87]	giv[86]|new[87]	coref	14-32[137_87]
10-11	1591-1598	highest	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-12	1599-1608	incidence	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-13	1609-1611	in	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-14	1612-1620	advanced	abstract[86]|abstract[87]|abstract[88]	giv[86]|new[87]|new[88]	_	_
10-15	1621-1624	age	abstract[86]|abstract[87]|abstract[88]	giv[86]|new[87]|new[88]	_	_
10-16	1625-1626	,	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-17	1627-1629	i.	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-18	1630-1632	e.	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-19	1633-1634	,	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-20	1635-1643	coronary	abstract[86]|abstract[87]|object|abstract[91]	giv[86]|new[87]|new|new[91]	_	_
10-21	1644-1649	heart	abstract[86]|abstract[87]|object|abstract[91]	giv[86]|new[87]|new|new[91]	_	_
10-22	1650-1658	diseases	abstract[86]|abstract[87]|abstract[91]	giv[86]|new[87]|new[91]	_	_
10-23	1659-1660	,	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-24	1661-1667	cancer	abstract[86]|abstract[87]|abstract	giv[86]|new[87]|new	_	_
10-25	1668-1669	,	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-26	1670-1681	respiratory	abstract[86]|abstract[87]|abstract[94]	giv[86]|new[87]|new[94]	_	_
10-27	1682-1688	system	abstract[86]|abstract[87]|object|abstract[94]	giv[86]|new[87]|new|new[94]	_	_
10-28	1689-1697	diseases	abstract[86]|abstract[87]|abstract[94]	giv[86]|new[87]|new[94]	_	_
10-29	1698-1699	,	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-30	1700-1710	depression	abstract[86]|abstract[87]|abstract	giv[86]|new[87]|new	_	_
10-31	1711-1712	,	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-32	1713-1716	and	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-33	1717-1734	neurodegenerative	abstract[86]|abstract[87]|abstract[96]	giv[86]|new[87]|new[96]	coref	17-23[171_96]
10-34	1735-1743	diseases	abstract[86]|abstract[87]|abstract[96]	giv[86]|new[87]|new[96]	_	_
10-35	1744-1748	such	abstract[86]|abstract[87]|abstract[96]	giv[86]|new[87]|new[96]	_	_
10-36	1749-1751	as	abstract[86]|abstract[87]|abstract[96]	giv[86]|new[87]|new[96]	_	_
10-37	1752-1761	Alzheimer	abstract[86]|abstract[87]|abstract[96]|abstract[97]	giv[86]|new[87]|new[96]|new[97]	_	_
10-38	1762-1764	’s	abstract[86]|abstract[87]|abstract[96]|abstract[97]	giv[86]|new[87]|new[96]|new[97]	_	_
10-39	1765-1772	disease	abstract[86]|abstract[87]|abstract[96]	giv[86]|new[87]|new[96]	_	_
10-40	1773-1774	.	_	_	_	_

#Text=Associated with OP , especially prevalent among older women , is bone fracture risk .
11-1	1775-1785	Associated	_	_	_	_
11-2	1786-1790	with	_	_	_	_
11-3	1791-1793	OP	abstract	giv	coref	12-11
11-4	1794-1795	,	_	_	_	_
11-5	1796-1806	especially	_	_	_	_
11-6	1807-1816	prevalent	_	_	_	_
11-7	1817-1822	among	_	_	_	_
11-8	1823-1828	older	person[99]	new[99]	coref	15-16[0_99]
11-9	1829-1834	women	person[99]	new[99]	_	_
11-10	1835-1836	,	_	_	_	_
11-11	1837-1839	is	_	_	_	_
11-12	1840-1844	bone	object|abstract[102]	new|new[102]	coref|coref|coref|coref	12-19|13-33[126_102]|12-19|13-33[126_102]
11-13	1845-1853	fracture	abstract|abstract[102]	new|new[102]	coref	15-42[153_0]
11-14	1854-1858	risk	abstract[102]	new[102]	_	_
11-15	1859-1860	.	_	_	_	_

#Text=This growing global health problem suggests that the prevention of OP and its complications and the maintenance of bone mass are public health concerns .
12-1	1861-1865	This	abstract[104]	new[104]	_	_
12-2	1866-1873	growing	abstract[104]	new[104]	_	_
12-3	1874-1880	global	abstract[104]	new[104]	_	_
12-4	1881-1887	health	abstract|abstract[104]	new|new[104]	coref	20-15[185_0]
12-5	1888-1895	problem	abstract[104]	new[104]	_	_
12-6	1896-1904	suggests	_	_	_	_
12-7	1905-1909	that	_	_	_	_
12-8	1910-1913	the	abstract[105]	new[105]	ana	12-13[0_105]
12-9	1914-1924	prevention	abstract[105]	new[105]	_	_
12-10	1925-1927	of	abstract[105]	new[105]	_	_
12-11	1928-1930	OP	abstract[105]|abstract	new[105]|giv	coref	13-1
12-12	1931-1934	and	_	_	_	_
12-13	1935-1938	its	abstract|abstract[108]	giv|new[108]	coref|coref	16-10[159_108]|16-10[159_108]
12-14	1939-1952	complications	abstract[108]	new[108]	_	_
12-15	1953-1956	and	_	_	_	_
12-16	1957-1960	the	abstract[109]	new[109]	coref	12-22[112_109]
12-17	1961-1972	maintenance	abstract[109]	new[109]	_	_
12-18	1973-1975	of	abstract[109]	new[109]	_	_
12-19	1976-1980	bone	abstract[109]|object|quantity[111]	new[109]|giv|new[111]	coref|coref|coref|coref	13-10|13-11[0_111]|13-10|13-11[0_111]
12-20	1981-1985	mass	abstract[109]|quantity[111]	new[109]|new[111]	_	_
12-21	1986-1989	are	_	_	_	_
12-22	1990-1996	public	abstract[112]	giv[112]	_	_
12-23	1997-2003	health	abstract[112]	giv[112]	_	_
12-24	2004-2012	concerns	abstract[112]	giv[112]	_	_
12-25	2013-2014	.	_	_	_	_

#Text=OP is a systemic disease characterized by a low bone mass index and destruction of the microarchitecture of bone mass — i. e. , bone mineral density ( BMD ) — posing a major risk of fractures .
13-1	2015-2017	OP	person	giv	coref	13-3[114_0]
13-2	2018-2020	is	_	_	_	_
13-3	2021-2022	a	abstract[114]	giv[114]	coref	14-20[0_114]
13-4	2023-2031	systemic	abstract[114]	giv[114]	_	_
13-5	2032-2039	disease	abstract[114]	giv[114]	_	_
13-6	2040-2053	characterized	_	_	_	_
13-7	2054-2056	by	_	_	_	_
13-8	2057-2058	a	abstract[117]	new[117]	_	_
13-9	2059-2062	low	abstract[117]	new[117]	_	_
13-10	2063-2067	bone	object|abstract[117]	giv|new[117]	coref	13-19
13-11	2068-2072	mass	quantity|abstract[117]	giv|new[117]	coref	13-19[121_0]
13-12	2073-2078	index	abstract[117]	new[117]	_	_
13-13	2079-2082	and	_	_	_	_
13-14	2083-2094	destruction	event[118]	new[118]	_	_
13-15	2095-2097	of	event[118]	new[118]	_	_
13-16	2098-2101	the	event[118]|abstract[119]	new[118]|new[119]	_	_
13-17	2102-2119	microarchitecture	event[118]|abstract[119]	new[118]|new[119]	_	_
13-18	2120-2122	of	event[118]|abstract[119]	new[118]|new[119]	_	_
13-19	2123-2127	bone	event[118]|abstract[119]|object|abstract[121]	new[118]|new[119]|giv|giv[121]	coref|coref|coref|coref	13-25|14-9[131_121]|13-25|14-9[131_121]
13-20	2128-2132	mass	event[118]|abstract[119]|abstract[121]	new[118]|new[119]|giv[121]	_	_
13-21	2133-2134	—	_	_	_	_
13-22	2135-2137	i.	_	_	_	_
13-23	2138-2140	e.	_	_	_	_
13-24	2141-2142	,	_	_	_	_
13-25	2143-2147	bone	object|abstract[124]	giv|new[124]	appos|coref|appos|coref	13-29[0_124]|14-9|13-29[0_124]|14-9
13-26	2148-2155	mineral	substance|abstract[124]	new|new[124]	_	_
13-27	2156-2163	density	abstract[124]	new[124]	_	_
13-28	2164-2165	(	_	_	_	_
13-29	2166-2169	BMD	abstract	giv	coref	19-17[180_0]
13-30	2170-2171	)	_	_	_	_
13-31	2172-2173	—	_	_	_	_
13-32	2174-2180	posing	_	_	_	_
13-33	2181-2182	a	abstract[126]	giv[126]	coref	17-15[168_126]
13-34	2183-2188	major	abstract[126]	giv[126]	_	_
13-35	2189-2193	risk	abstract[126]	giv[126]	_	_
13-36	2194-2196	of	abstract[126]	giv[126]	_	_
13-37	2197-2206	fractures	abstract[126]|event	giv[126]|new	coref	14-13
13-38	2207-2208	.	_	_	_	_

#Text=There are no symptoms indicating a reduction in bone mass , and fractures are the only clinical consequences of OP ; therefore , despite being the most common bone disease , the incidence is difficult to establish , and the prevalence is often based on estimates using indirect indicators such as fractures .
14-1	2209-2214	There	_	_	_	_
14-2	2215-2218	are	_	_	_	_
14-3	2219-2221	no	abstract[128]	new[128]	_	_
14-4	2222-2230	symptoms	abstract[128]	new[128]	_	_
14-5	2231-2241	indicating	_	_	_	_
14-6	2242-2243	a	abstract[129]	new[129]	coref	17-12[167_129]
14-7	2244-2253	reduction	abstract[129]	new[129]	_	_
14-8	2254-2256	in	abstract[129]	new[129]	_	_
14-9	2257-2261	bone	abstract[129]|object|abstract[131]	new[129]|giv|giv[131]	coref|coref|coref|coref	14-29|16-16[161_131]|14-29|16-16[161_131]
14-10	2262-2266	mass	abstract[129]|abstract[131]	new[129]|giv[131]	_	_
14-11	2267-2268	,	_	_	_	_
14-12	2269-2272	and	_	_	_	_
14-13	2273-2282	fractures	abstract	giv	coref	14-15[133_0]
14-14	2283-2286	are	_	_	_	_
14-15	2287-2290	the	abstract[133]	giv[133]	coref	14-52[0_133]
14-16	2291-2295	only	abstract[133]	giv[133]	_	_
14-17	2296-2304	clinical	abstract[133]	giv[133]	_	_
14-18	2305-2317	consequences	abstract[133]	giv[133]	_	_
14-19	2318-2320	of	abstract[133]	giv[133]	_	_
14-20	2321-2323	OP	abstract[133]|abstract	giv[133]|giv	coref	14-26[136_0]
14-21	2324-2325	;	abstract[133]	giv[133]	_	_
14-22	2326-2335	therefore	abstract[133]	giv[133]	_	_
14-23	2336-2337	,	_	_	_	_
14-24	2338-2345	despite	_	_	_	_
14-25	2346-2351	being	_	_	_	_
14-26	2352-2355	the	abstract[136]	giv[136]	coref	16-7[158_136]
14-27	2356-2360	most	abstract[136]	giv[136]	_	_
14-28	2361-2367	common	abstract[136]	giv[136]	_	_
14-29	2368-2372	bone	object|abstract[136]	giv|giv[136]	coref	15-45
14-30	2373-2380	disease	abstract[136]	giv[136]	_	_
14-31	2381-2382	,	_	_	_	_
14-32	2383-2386	the	abstract[137]	giv[137]	_	_
14-33	2387-2396	incidence	abstract[137]	giv[137]	_	_
14-34	2397-2399	is	_	_	_	_
14-35	2400-2409	difficult	_	_	_	_
14-36	2410-2412	to	_	_	_	_
14-37	2413-2422	establish	_	_	_	_
14-38	2423-2424	,	_	_	_	_
14-39	2425-2428	and	_	_	_	_
14-40	2429-2432	the	abstract[138]	new[138]	coref	15-4[0_138]
14-41	2433-2443	prevalence	abstract[138]	new[138]	_	_
14-42	2444-2446	is	_	_	_	_
14-43	2447-2452	often	_	_	_	_
14-44	2453-2458	based	_	_	_	_
14-45	2459-2461	on	_	_	_	_
14-46	2462-2471	estimates	abstract	new	_	_
14-47	2472-2477	using	_	_	_	_
14-48	2478-2486	indirect	abstract[140]	new[140]	_	_
14-49	2487-2497	indicators	abstract[140]	new[140]	_	_
14-50	2498-2502	such	abstract[140]	new[140]	_	_
14-51	2503-2505	as	abstract[140]	new[140]	_	_
14-52	2506-2515	fractures	abstract[140]|event	new[140]|giv	coref	24-18[213_0]
14-53	2516-2517	.	_	_	_	_

#Text=In Spain , prevalence , as determined by densitometry , is about 30 % in women aged 50 years old , increasing to 50 % in women older than 70 years old . About 40 % of Caucasian women will suffer at least one bone fracture after their 50s .
15-1	2518-2520	In	_	_	_	_
15-2	2521-2526	Spain	place	new	_	_
15-3	2527-2528	,	_	_	_	_
15-4	2529-2539	prevalence	abstract	giv	coref	15-12[145_0]
15-5	2540-2541	,	_	_	_	_
15-6	2542-2544	as	_	_	_	_
15-7	2545-2555	determined	_	_	_	_
15-8	2556-2558	by	_	_	_	_
15-9	2559-2571	densitometry	abstract	new	_	_
15-10	2572-2573	,	_	_	_	_
15-11	2574-2576	is	_	_	_	_
15-12	2577-2582	about	abstract[145]	giv[145]	coref	16-4[157_145]
15-13	2583-2585	30	abstract[145]	giv[145]	_	_
15-14	2586-2587	%	abstract[145]	giv[145]	_	_
15-15	2588-2590	in	abstract[145]	giv[145]	_	_
15-16	2591-2596	women	abstract[145]|person	giv[145]|giv	coref	15-27[149_0]
15-17	2597-2601	aged	_	_	_	_
15-18	2602-2604	50	time[147]	new[147]	_	_
15-19	2605-2610	years	time[147]	new[147]	_	_
15-20	2611-2614	old	_	_	_	_
15-21	2615-2616	,	_	_	_	_
15-22	2617-2627	increasing	_	_	_	_
15-23	2628-2630	to	_	_	_	_
15-24	2631-2633	50	quantity[148]	new[148]	_	_
15-25	2634-2635	%	quantity[148]	new[148]	_	_
15-26	2636-2638	in	quantity[148]	new[148]	_	_
15-27	2639-2644	women	quantity[148]|person[149]	new[148]|giv[149]	ana	15-48[0_149]
15-28	2645-2650	older	quantity[148]|person[149]	new[148]|giv[149]	_	_
15-29	2651-2655	than	quantity[148]|person[149]	new[148]|giv[149]	_	_
15-30	2656-2658	70	quantity[148]|person[149]|time[150]	new[148]|giv[149]|new[150]	_	_
15-31	2659-2664	years	quantity[148]|person[149]|time[150]	new[148]|giv[149]|new[150]	_	_
15-32	2665-2668	old	quantity[148]|person[149]	new[148]|giv[149]	_	_
15-33	2669-2670	.	quantity[148]|person[149]	new[148]|giv[149]	_	_
15-34	2671-2676	About	quantity[148]|person[149]|quantity[151]	new[148]|giv[149]|new[151]	_	_
15-35	2677-2679	40	quantity[148]|person[149]|quantity[151]	new[148]|giv[149]|new[151]	_	_
15-36	2680-2681	%	quantity[148]|person[149]|quantity[151]	new[148]|giv[149]|new[151]	_	_
15-37	2682-2684	of	quantity[148]|person[149]|quantity[151]	new[148]|giv[149]|new[151]	_	_
15-38	2685-2694	Caucasian	quantity[148]|person[149]|quantity[151]	new[148]|giv[149]|new[151]	_	_
15-39	2695-2700	women	quantity[148]|person[149]|quantity[151]	new[148]|giv[149]|new[151]	_	_
15-40	2701-2705	will	quantity[148]|person[149]	new[148]|giv[149]	_	_
15-41	2706-2712	suffer	quantity[148]|person[149]	new[148]|giv[149]	_	_
15-42	2713-2715	at	quantity[148]|person[149]|abstract[153]	new[148]|giv[149]|giv[153]	coref	19-12[0_153]
15-43	2716-2721	least	quantity[148]|person[149]|abstract[153]	new[148]|giv[149]|giv[153]	_	_
15-44	2722-2725	one	quantity[148]|person[149]|abstract[153]	new[148]|giv[149]|giv[153]	_	_
15-45	2726-2730	bone	quantity[148]|person[149]|object|abstract[153]	new[148]|giv[149]|giv|giv[153]	coref	16-16
15-46	2731-2739	fracture	quantity[148]|person[149]|abstract[153]	new[148]|giv[149]|giv[153]	_	_
15-47	2740-2745	after	_	_	_	_
15-48	2746-2751	their	person|time[155]	giv|new[155]	coref|coref	20-18[187_0]|20-18[187_0]
15-49	2752-2755	50s	time[155]	new[155]	_	_
15-50	2756-2757	.	_	_	_	_

#Text=Strategies to minimize the prevalence of the disease and its complications would be to enhance bone mass and reduce loss at advanced ages .
16-1	2758-2768	Strategies	abstract	new	_	_
16-2	2769-2771	to	_	_	_	_
16-3	2772-2780	minimize	_	_	_	_
16-4	2781-2784	the	abstract[157]	giv[157]	_	_
16-5	2785-2795	prevalence	abstract[157]	giv[157]	_	_
16-6	2796-2798	of	abstract[157]	giv[157]	_	_
16-7	2799-2802	the	abstract[157]|abstract[158]	giv[157]|giv[158]	_	_
16-8	2803-2810	disease	abstract[157]|abstract[158]	giv[157]|giv[158]	_	_
16-9	2811-2814	and	abstract[157]|abstract[158]	giv[157]|giv[158]	_	_
16-10	2815-2818	its	abstract[157]|abstract[158]|abstract[159]	giv[157]|giv[158]|giv[159]	_	_
16-11	2819-2832	complications	abstract[157]|abstract[158]|abstract[159]	giv[157]|giv[158]|giv[159]	_	_
16-12	2833-2838	would	_	_	_	_
16-13	2839-2841	be	_	_	_	_
16-14	2842-2844	to	_	_	_	_
16-15	2845-2852	enhance	_	_	_	_
16-16	2853-2857	bone	substance|abstract[161]	giv|giv[161]	coref|coref	20-15|20-15
16-17	2858-2862	mass	abstract[161]	giv[161]	_	_
16-18	2863-2866	and	_	_	_	_
16-19	2867-2873	reduce	_	_	_	_
16-20	2874-2878	loss	abstract	new	_	_
16-21	2879-2881	at	_	_	_	_
16-22	2882-2890	advanced	abstract[163]	new[163]	_	_
16-23	2891-2895	ages	abstract[163]	new[163]	_	_
16-24	2896-2897	.	_	_	_	_

#Text=There is convincing scientific evidence supporting the MD ’s role in the reduction of overall risk for diabetes , cardiovascular , and neurodegenerative diseases .
17-1	2898-2903	There	_	_	_	_
17-2	2904-2906	is	_	_	_	_
17-3	2907-2917	convincing	_	_	_	_
17-4	2918-2928	scientific	abstract[164]	new[164]	coref	18-10[174_164]
17-5	2929-2937	evidence	abstract[164]	new[164]	_	_
17-6	2938-2948	supporting	_	_	_	_
17-7	2949-2952	the	abstract[166]	new[166]	coref	20-8[182_166]
17-8	2953-2955	MD	place[165]|abstract[166]	new[165]|new[166]	_	_
17-9	2956-2958	’s	place[165]|abstract[166]	new[165]|new[166]	_	_
17-10	2959-2963	role	abstract[166]	new[166]	_	_
17-11	2964-2966	in	abstract[166]	new[166]	_	_
17-12	2967-2970	the	abstract[166]|abstract[167]	new[166]|giv[167]	coref	18-20[176_167]
17-13	2971-2980	reduction	abstract[166]|abstract[167]	new[166]|giv[167]	_	_
17-14	2981-2983	of	abstract[166]|abstract[167]	new[166]|giv[167]	_	_
17-15	2984-2991	overall	abstract[166]|abstract[167]|abstract[168]	new[166]|giv[167]|giv[168]	_	_
17-16	2992-2996	risk	abstract[166]|abstract[167]|abstract[168]	new[166]|giv[167]|giv[168]	_	_
17-17	2997-3000	for	abstract[166]|abstract[167]|abstract[168]	new[166]|giv[167]|giv[168]	_	_
17-18	3001-3009	diabetes	abstract[166]|abstract[167]|abstract[168]|abstract	new[166]|giv[167]|giv[168]|new	_	_
17-19	3010-3011	,	abstract[166]|abstract[167]|abstract[168]	new[166]|giv[167]|giv[168]	_	_
17-20	3012-3026	cardiovascular	abstract[166]|abstract[167]|abstract[168]|abstract	new[166]|giv[167]|giv[168]|new	_	_
17-21	3027-3028	,	abstract[166]|abstract[167]|abstract[168]	new[166]|giv[167]|giv[168]	_	_
17-22	3029-3032	and	abstract[166]|abstract[167]|abstract[168]	new[166]|giv[167]|giv[168]	_	_
17-23	3033-3050	neurodegenerative	abstract[166]|abstract[167]|abstract[168]|abstract[171]	new[166]|giv[167]|giv[168]|giv[171]	_	_
17-24	3051-3059	diseases	abstract[166]|abstract[167]|abstract[168]|abstract[171]	new[166]|giv[167]|giv[168]|giv[171]	_	_
17-25	3060-3061	.	_	_	_	_

#Text=Regarding site-specific cancers and inflammatory and metabolic conditions , the evidence is suggestive or weak and is unconvincing regarding low-density lipid reduction .
18-1	3062-3071	Regarding	_	_	_	_
18-2	3072-3085	site-specific	abstract[172]	new[172]	_	_
18-3	3086-3093	cancers	abstract[172]	new[172]	_	_
18-4	3094-3097	and	_	_	_	_
18-5	3098-3110	inflammatory	abstract[173]	new[173]	_	_
18-6	3111-3114	and	abstract[173]	new[173]	_	_
18-7	3115-3124	metabolic	abstract[173]	new[173]	_	_
18-8	3125-3135	conditions	abstract[173]	new[173]	_	_
18-9	3136-3137	,	_	_	_	_
18-10	3138-3141	the	abstract[174]	giv[174]	coref	20-3[181_174]
18-11	3142-3150	evidence	abstract[174]	giv[174]	_	_
18-12	3151-3153	is	_	_	_	_
18-13	3154-3164	suggestive	_	_	_	_
18-14	3165-3167	or	_	_	_	_
18-15	3168-3172	weak	_	_	_	_
18-16	3173-3176	and	_	_	_	_
18-17	3177-3179	is	_	_	_	_
18-18	3180-3192	unconvincing	_	_	_	_
18-19	3193-3202	regarding	_	_	_	_
18-20	3203-3214	low-density	abstract[176]	giv[176]	_	_
18-21	3215-3220	lipid	abstract|abstract[176]	new|giv[176]	_	_
18-22	3221-3230	reduction	abstract[176]	giv[176]	_	_
18-23	3231-3232	.	_	_	_	_

#Text=The MD has been shown to modestly reduce the risk of fracture and is associated with higher BMD .
19-1	3233-3236	The	abstract[177]	giv[177]	coref	20-11[183_177]
19-2	3237-3239	MD	abstract[177]	giv[177]	_	_
19-3	3240-3243	has	_	_	_	_
19-4	3244-3248	been	_	_	_	_
19-5	3249-3254	shown	_	_	_	_
19-6	3255-3257	to	_	_	_	_
19-7	3258-3266	modestly	_	_	_	_
19-8	3267-3273	reduce	_	_	_	_
19-9	3274-3277	the	abstract[178]	new[178]	coref	21-23[194_178]
19-10	3278-3282	risk	abstract[178]	new[178]	_	_
19-11	3283-3285	of	abstract[178]	new[178]	_	_
19-12	3286-3294	fracture	abstract[178]|abstract	new[178]|giv	coref	21-23
19-13	3295-3298	and	_	_	_	_
19-14	3299-3301	is	_	_	_	_
19-15	3302-3312	associated	_	_	_	_
19-16	3313-3317	with	_	_	_	_
19-17	3318-3324	higher	abstract[180]	giv[180]	_	_
19-18	3325-3328	BMD	abstract[180]	giv[180]	_	_
19-19	3329-3330	.	_	_	_	_

#Text=Thus , the overall evidence points toward the role of the MD in maintaining bone health , especially in postmenopausal women .
20-1	3331-3335	Thus	_	_	_	_
20-2	3336-3337	,	_	_	_	_
20-3	3338-3341	the	abstract[181]	giv[181]	_	_
20-4	3342-3349	overall	abstract[181]	giv[181]	_	_
20-5	3350-3358	evidence	abstract[181]	giv[181]	_	_
20-6	3359-3365	points	_	_	_	_
20-7	3366-3372	toward	_	_	_	_
20-8	3373-3376	the	abstract[182]	giv[182]	_	_
20-9	3377-3381	role	abstract[182]	giv[182]	_	_
20-10	3382-3384	of	abstract[182]	giv[182]	_	_
20-11	3385-3388	the	abstract[182]|abstract[183]	giv[182]|giv[183]	coref	21-21[0_183]
20-12	3389-3391	MD	abstract[182]|abstract[183]	giv[182]|giv[183]	_	_
20-13	3392-3394	in	_	_	_	_
20-14	3395-3406	maintaining	_	_	_	_
20-15	3407-3411	bone	object|abstract[185]	giv|giv[185]	coref|coref	24-18|24-18
20-16	3412-3418	health	abstract[185]	giv[185]	_	_
20-17	3419-3420	,	_	_	_	_
20-18	3421-3431	especially	person[187]	giv[187]	_	_
20-19	3432-3434	in	person[187]	giv[187]	_	_
20-20	3435-3449	postmenopausal	event|person[187]	new|giv[187]	_	_
20-21	3450-3455	women	person[187]	giv[187]	_	_
20-22	3456-3457	.	_	_	_	_

#Text=Residual confounding factors in observational studies has become a major concern , with many international studies analyzing the relationship between diet and fracture risk .
21-1	3458-3466	Residual	abstract[188]	new[188]	coref	27-19[238_188]
21-2	3467-3478	confounding	abstract[188]	new[188]	_	_
21-3	3479-3486	factors	abstract[188]	new[188]	_	_
21-4	3487-3489	in	abstract[188]	new[188]	_	_
21-5	3490-3503	observational	abstract[188]|event[189]	new[188]|new[189]	coref	21-14[190_189]
21-6	3504-3511	studies	abstract[188]|event[189]	new[188]|new[189]	_	_
21-7	3512-3515	has	_	_	_	_
21-8	3516-3522	become	_	_	_	_
21-9	3523-3524	a	_	_	_	_
21-10	3525-3530	major	_	_	_	_
21-11	3531-3538	concern	_	_	_	_
21-12	3539-3540	,	_	_	_	_
21-13	3541-3545	with	_	_	_	_
21-14	3546-3550	many	event[190]	giv[190]	coref	22-15[200_190]
21-15	3551-3564	international	event[190]	giv[190]	_	_
21-16	3565-3572	studies	event[190]	giv[190]	_	_
21-17	3573-3582	analyzing	_	_	_	_
21-18	3583-3586	the	abstract[191]	new[191]	coref	27-8[232_191]
21-19	3587-3599	relationship	abstract[191]	new[191]	_	_
21-20	3600-3607	between	abstract[191]	new[191]	_	_
21-21	3608-3612	diet	abstract[191]|abstract	new[191]|giv	coref	23-18[208_0]
21-22	3613-3616	and	abstract[191]	new[191]	_	_
21-23	3617-3625	fracture	abstract[191]|abstract|abstract[194]	new[191]|giv|giv[194]	coref|coref	26-10|26-10
21-24	3626-3630	risk	abstract[191]|abstract[194]	new[191]|giv[194]	_	_
21-25	3631-3632	.	_	_	_	_

#Text=For instance , bias should be taken into account when considering meta-analysis results on prospective cohort studies beyond the Mediterranean region .
22-1	3633-3636	For	_	_	_	_
22-2	3637-3645	instance	_	_	_	_
22-3	3646-3647	,	_	_	_	_
22-4	3648-3652	bias	abstract	new	_	_
22-5	3653-3659	should	_	_	_	_
22-6	3660-3662	be	_	_	_	_
22-7	3663-3668	taken	_	_	_	_
22-8	3669-3673	into	_	_	_	_
22-9	3674-3681	account	abstract	new	coref	25-21
22-10	3682-3686	when	_	_	_	_
22-11	3687-3698	considering	_	_	_	_
22-12	3699-3712	meta-analysis	abstract|abstract[198]	new|new[198]	_	_
22-13	3713-3720	results	abstract[198]	new[198]	_	_
22-14	3721-3723	on	abstract[198]	new[198]	_	_
22-15	3724-3735	prospective	abstract[198]|event[200]	new[198]|giv[200]	coref	26-22[227_200]
22-16	3736-3742	cohort	abstract[198]|object|event[200]	new[198]|new|giv[200]	_	_
22-17	3743-3750	studies	abstract[198]|event[200]	new[198]|giv[200]	_	_
22-18	3751-3757	beyond	abstract[198]|event[200]	new[198]|giv[200]	_	_
22-19	3758-3761	the	abstract[198]|event[200]|place[201]	new[198]|giv[200]|new[201]	ana	23-1[0_201]
22-20	3762-3775	Mediterranean	abstract[198]|event[200]|place[201]	new[198]|giv[200]|new[201]	_	_
22-21	3776-3782	region	abstract[198]|event[200]|place[201]	new[198]|giv[200]|new[201]	_	_
22-22	3783-3784	.	_	_	_	_

#Text=This is due to the paucity of data and the lack of consensus on the definition of the MD .
23-1	3785-3789	This	place	giv	_	_
23-2	3790-3792	is	_	_	_	_
23-3	3793-3796	due	_	_	_	_
23-4	3797-3799	to	_	_	_	_
23-5	3800-3803	the	quantity[203]	new[203]	_	_
23-6	3804-3811	paucity	quantity[203]	new[203]	_	_
23-7	3812-3814	of	quantity[203]	new[203]	_	_
23-8	3815-3819	data	quantity[203]|abstract	new[203]|new	_	_
23-9	3820-3823	and	_	_	_	_
23-10	3824-3827	the	abstract[205]	new[205]	_	_
23-11	3828-3832	lack	abstract[205]	new[205]	_	_
23-12	3833-3835	of	abstract[205]	new[205]	_	_
23-13	3836-3845	consensus	abstract[205]|abstract[206]	new[205]|new[206]	_	_
23-14	3846-3848	on	abstract[205]|abstract[206]	new[205]|new[206]	_	_
23-15	3849-3852	the	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
23-16	3853-3863	definition	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
23-17	3864-3866	of	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
23-18	3867-3870	the	abstract[205]|abstract[206]|abstract[207]|abstract[208]	new[205]|new[206]|new[207]|giv[208]	coref	25-2[214_208]
23-19	3871-3873	MD	abstract[205]|abstract[206]|abstract[207]|abstract[208]	new[205]|new[206]|new[207]|giv[208]	_	_
23-20	3874-3875	.	_	_	_	_

#Text=Furthermore , physical activity has been demonstrated to be a robust indicator of a lower risk of bone fractures .
24-1	3876-3887	Furthermore	_	_	_	_
24-2	3888-3889	,	_	_	_	_
24-3	3890-3898	physical	abstract[209]	new[209]	coref	25-10[0_209]
24-4	3899-3907	activity	abstract[209]	new[209]	_	_
24-5	3908-3911	has	_	_	_	_
24-6	3912-3916	been	_	_	_	_
24-7	3917-3929	demonstrated	_	_	_	_
24-8	3930-3932	to	_	_	_	_
24-9	3933-3935	be	_	_	_	_
24-10	3936-3937	a	abstract[210]	new[210]	_	_
24-11	3938-3944	robust	abstract[210]	new[210]	_	_
24-12	3945-3954	indicator	abstract[210]	new[210]	_	_
24-13	3955-3957	of	abstract[210]	new[210]	_	_
24-14	3958-3959	a	abstract[210]|abstract[211]	new[210]|new[211]	coref	26-9[224_211]
24-15	3960-3965	lower	abstract[210]|abstract[211]	new[210]|new[211]	_	_
24-16	3966-3970	risk	abstract[210]|abstract[211]	new[210]|new[211]	_	_
24-17	3971-3973	of	abstract[210]|abstract[211]	new[210]|new[211]	_	_
24-18	3974-3978	bone	abstract[210]|abstract[211]|object|event[213]	new[210]|new[211]|giv|giv[213]	coref|coref	26-9|26-9
24-19	3979-3988	fractures	abstract[210]|abstract[211]|event[213]	new[210]|new[211]|giv[213]	_	_
24-20	3989-3990	.	_	_	_	_

#Text=Since a healthier diet is related to higher physical activity levels , the latter needs also to be taken into account .
25-1	3991-3996	Since	_	_	_	_
25-2	3997-3998	a	abstract[214]	giv[214]	coref	27-12[0_214]
25-3	3999-4008	healthier	abstract[214]	giv[214]	_	_
25-4	4009-4013	diet	abstract[214]	giv[214]	_	_
25-5	4014-4016	is	_	_	_	_
25-6	4017-4024	related	_	_	_	_
25-7	4025-4027	to	_	_	_	_
25-8	4028-4034	higher	abstract[216]	new[216]	_	_
25-9	4035-4043	physical	abstract[216]	new[216]	_	_
25-10	4044-4052	activity	abstract|abstract[216]	giv|new[216]	_	_
25-11	4053-4059	levels	abstract[216]	new[216]	_	_
25-12	4060-4061	,	_	_	_	_
25-13	4062-4065	the	_	_	_	_
25-14	4066-4072	latter	_	_	_	_
25-15	4073-4078	needs	_	_	_	_
25-16	4079-4083	also	_	_	_	_
25-17	4084-4086	to	_	_	_	_
25-18	4087-4089	be	_	_	_	_
25-19	4090-4095	taken	_	_	_	_
25-20	4096-4100	into	_	_	_	_
25-21	4101-4108	account	abstract	giv	_	_
25-22	4109-4110	.	_	_	_	_

#Text=The observed inverse association between dietary quality and bone fracture risk should be interpreted with caution because the case-control design of most studies ’ findings cannot indicate causality .
26-1	4111-4114	The	abstract[219]	new[219]	_	_
26-2	4115-4123	observed	abstract[219]	new[219]	_	_
26-3	4124-4131	inverse	place|abstract[219]	new|new[219]	_	_
26-4	4132-4143	association	abstract[219]	new[219]	_	_
26-5	4144-4151	between	abstract[219]	new[219]	_	_
26-6	4152-4159	dietary	abstract[219]|object|abstract[221]	new[219]|giv|new[221]	_	_
26-7	4160-4167	quality	abstract[219]|abstract[221]	new[219]|new[221]	_	_
26-8	4168-4171	and	abstract[219]	new[219]	_	_
26-9	4172-4176	bone	abstract[219]|object|abstract[224]	new[219]|giv|giv[224]	coref|coref|coref|coref	27-14|27-11[236_224]|27-14|27-11[236_224]
26-10	4177-4185	fracture	abstract[219]|abstract|abstract[224]	new[219]|giv|giv[224]	coref	27-15
26-11	4186-4190	risk	abstract[219]|abstract[224]	new[219]|giv[224]	_	_
26-12	4191-4197	should	_	_	_	_
26-13	4198-4200	be	_	_	_	_
26-14	4201-4212	interpreted	_	_	_	_
26-15	4213-4217	with	_	_	_	_
26-16	4218-4225	caution	abstract	new	_	_
26-17	4226-4233	because	_	_	_	_
26-18	4234-4237	the	abstract[226]	new[226]	_	_
26-19	4238-4250	case-control	abstract[226]	new[226]	_	_
26-20	4251-4257	design	abstract[226]	new[226]	_	_
26-21	4258-4260	of	abstract[226]	new[226]	_	_
26-22	4261-4265	most	abstract[226]|event[227]|abstract[228]	new[226]|giv[227]|new[228]	_	_
26-23	4266-4273	studies	abstract[226]|event[227]|abstract[228]	new[226]|giv[227]|new[228]	_	_
26-24	4274-4275	’	abstract[226]|event[227]|abstract[228]	new[226]|giv[227]|new[228]	_	_
26-25	4276-4284	findings	abstract[226]|abstract[228]	new[226]|new[228]	_	_
26-26	4285-4291	cannot	_	_	_	_
26-27	4292-4300	indicate	_	_	_	_
26-28	4301-4310	causality	abstract	new	_	_
26-29	4311-4312	.	_	_	_	_

#Text=There is a lack of research into the relationship between the MD and bone fracture risk that clarifies causation or confounding factors .
27-1	4313-4318	There	_	_	_	_
27-2	4319-4321	is	_	_	_	_
27-3	4322-4323	a	abstract[230]	new[230]	_	_
27-4	4324-4328	lack	abstract[230]	new[230]	_	_
27-5	4329-4331	of	abstract[230]	new[230]	_	_
27-6	4332-4340	research	abstract[230]|abstract	new[230]|new	_	_
27-7	4341-4345	into	_	_	_	_
27-8	4346-4349	the	abstract[232]	giv[232]	_	_
27-9	4350-4362	relationship	abstract[232]	giv[232]	_	_
27-10	4363-4370	between	abstract[232]	giv[232]	_	_
27-11	4371-4374	the	abstract[232]|abstract[236]	giv[232]|giv[236]	_	_
27-12	4375-4377	MD	abstract[232]|place|abstract[236]	giv[232]|giv|giv[236]	_	_
27-13	4378-4381	and	abstract[232]|abstract[236]	giv[232]|giv[236]	_	_
27-14	4382-4386	bone	abstract[232]|object|abstract[236]	giv[232]|giv|giv[236]	_	_
27-15	4387-4395	fracture	abstract[232]|abstract|abstract[236]	giv[232]|giv|giv[236]	_	_
27-16	4396-4400	risk	abstract[232]|abstract[236]	giv[232]|giv[236]	_	_
27-17	4401-4405	that	_	_	_	_
27-18	4406-4415	clarifies	_	_	_	_
27-19	4416-4425	causation	abstract|abstract[238]	new|giv[238]	_	_
27-20	4426-4428	or	abstract[238]	giv[238]	_	_
27-21	4429-4440	confounding	abstract[238]	giv[238]	_	_
27-22	4441-4448	factors	abstract[238]	giv[238]	_	_
27-23	4449-4450	.	_	_	_	_
